

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### STA daratumumab monotherapy for treating relapsed and refractory multiple myeloma (CDF review of TA510)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

CDF review – no draft scope consultation but during TA510 the following was identified.

*During scoping it was identified that multiple myeloma is more common in men than in women and the incidence is also reported to be higher in people of African family origin. This was not considered an equality issue that can be considered by the committee as issues related to differences in prevalence cannot be addressed in a technology appraisal. The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.*

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

**Approved by Associate Director (name):** Henry Edwards

**Date:** 13/09/2021